Methods of spray drying pharmaceutical compositions
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/14
A61K-009/12
A61K-009/127
A61K-047/16
출원번호
US-0219736
(1998-12-22)
발명자
/ 주소
Tarara, Thomas E.
Weers, Jeffry G.
Kabalnov, Alexey
Schutt, Ernest G.
Dellamary, Luis A.
출원인 / 주소
Inhale Therapeutic Systems, Inc.
대리인 / 주소
Rafa, Michael J.Cagan, Felissa H.
인용정보
피인용 횟수 :
125인용 특허 :
127
초록▼
Spray drying methods for forming powder compositions for pharmaceutical applications are disclosed. According to one aspect of the invention, the spray drying feed stock comprises a bioactive agent, surfactant, and a blowing agent. Another aspect of the invention is directed to spray drying a feed s
Spray drying methods for forming powder compositions for pharmaceutical applications are disclosed. According to one aspect of the invention, the spray drying feed stock comprises a bioactive agent, surfactant, and a blowing agent. Another aspect of the invention is directed to spray drying a feed stock comprising a phospholipid and calcium chloride.
대표청구항▼
Spray drying methods for forming powder compositions for pharmaceutical applications are disclosed. According to one aspect of the invention, the spray drying feed stock comprises a bioactive agent, surfactant, and a blowing agent. Another aspect of the invention is directed to spray drying a feed s
Spray drying methods for forming powder compositions for pharmaceutical applications are disclosed. According to one aspect of the invention, the spray drying feed stock comprises a bioactive agent, surfactant, and a blowing agent. Another aspect of the invention is directed to spray drying a feed stock comprising a phospholipid and calcium chloride. articulate solids having prior to compaction, an average particle size of at least about 175 microns, and a binder amount of a saturated, normally solid fatty amide effective to form said compacted article. 2. A method of claim 1 wherein the 1,3-dibromo-5,5-dimethylhydantoin used in said treatment is in non-compacted form and has an average particle size of at least about 175 microns. 3. A method of claim 2 wherein said average particle size is at least about 200 microns. 4. A method of claim 2 wherein said average particle size is at least about 300 microns. 5. A method of claim 1 wherein the 1,3-dibromo-5,5-dimethylhydantoin used in the treatment is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids having, prior to compaction, an average particle size of at least 175 microns, and a binder amount of a saturated, normally solid, fatty amide effective to form said compacted article. 6. A method of claim 5 wherein said average particle size is at least about 200 microns. 7. A method of claim 1 wherein the 1,3-dibromo-5,5-dimethylhydantoin used in the treatment is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids and a binder amount of a micronized synthetic polyolefin-based hydrocarbon wax and/or a micronized synthetic polyfluorocarbon wax effective to form said compacted article, said wax being compatible with said 1,3-dibromo-5,5-dimethylhydantoin. 8. A method of claim 7 wherein the 1,3-dibromo-5,5-dimethylhydantoin particulate solids used in forming said article had, prior to compaction, an average particle size of at least about 175 microns. 9. A method of claim 5 wherein said average particle size is at least about 300 microns. 10. A method of claim 7 wherein said wax is polyethylene ax having, prior to compaction, an average particle size of no greater than about 15 microns, a maximum particle size of no greater than about 40 microns, and a density in the range of about 0.9 to about 1.4 grams per cc at 25° C. 11. A method of claim 7 wherein said wax is a polyethylene wax that melts at a temperature in the range of about 109° C. to about 111° C. 12. A method of claim 7 wherein said wax is polypropylene wax having, prior to compaction, an average particle size in the range of about 5.0 to about 7.0 microns, a maximum particle size of about 22 microns, and a density in the range of about 0.9 to about 1.4 grams per cc at 25° C. 13. A method of claim 7 wherein said wax is a polypropylene wax that melts at a temperature in the range of about 140° C. to about 143° C., that prior to compaction has an average particle size in the range of about 5.0 to about 7.0 microns, and that prior to compaction has a maximum particle size of about 22 microns. 14. A method of claim 2 wherein said average particle size is at least about 400 microns. 15. A method of claim 1 wherein the 1,3,-dibromo-5,5-dimethylhydantoin used in the treatment is in the form of a shape-retentive pressure compacted article devoid of any binder and consists essentially of compacted 1,3-dibromo-5,5-dimethylhydantoin solids having prior to compaction an average particle size of at least about 175 microns. 16. A method of claim 15 wherein said average particle size is at least about 200 microns. 17. A method of claim 15 wherein said average particle size is at least about 300 microns. 18. A method of claim 15 wherein said average particle size is at least about 400 microns. 19. A method of claim 8 wherein said average particle size is at least about 200 microns. 20. A method of claim 8 wherein said average particle size is at least about 300 microns. 21. A method of claim 8 wherein said average particle size is at least about 400 microns. 22. A method of claim 5 wherein said average particle size is at least about 400 microns. 23. A method of combating at least Escherichia coli and/or Ent erococcus faecium in an aqueous medium, which method comprises introducing into said medium a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin that is less than the amount of N,N'-bromochloro-5,5-dimethylhydantoin required to achieve the same degree of effectiveness, wherein the 1,3-dibromo-5,5-dimethylhydantoin used in conducting the method is the sole disinfecting agent for sanitizing the aqueous medium, and wherein the 1,3-dibromo-5,5-dimethylhydantoin used: a) is in non-compacted form and has an average particle size of at least about 175 microns, or b) is in the form of a shape-retentive pressure compacted article devoid of any binder and consist essentially of compacted 1,3-dibromo-5,5-dimethylhydantoin solids having prior to compaction an average particle size of at least about 175 microns; or c) is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids and a binder amount of a micronized synthetic polyolefin-based hydrocarbon wax and/or a micronized synthetic polyfluorocarbon wax effective to form said compacted article, said wax being compatible with said 1,3-dibromo-5,5-dimethylhydantoin, or d) is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids having prior to compaction, an average particle size of at least about 175 microns, and a binder amount of a saturated, normally solid fatty amide effective to form said compacted article. 24. A method of eradicating or at least reducing biofilm on a surface contacted by an aqueous medium or water, which method comprises introducing into said medium or water a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin effective to eradicate or at least reduce such biofilm, said amount of 1,3-dibromo-5,5-dimethylhydantoin being less than the amount of N,N'-bromochloro-5,5-dimethylhydantoin required to achieve the same degree of effectiveness, wherein the 1,3-dibromo-5,5-dimethylhydantoin used in conducting the method is the sole disinfecting agent for sanitizing the aqueous medium, and wherein the 1,3-dibromo-5,5-dimethylhydantoin used: a) is in non-compacted form and has an average particle size of at least about 175 microns; or b) is in the form of a shape-retentive pressure compacted article devoid of any binder and consists essentially of compacted 1,3-dibromo-5,5-dimethylhydantoin solids having prior to compaction an average particle size of at least about 175 microns; or c) is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids and a binder amount of a micronized synthetic polyolefin-based hydrocarbon wax and/or a micronized synthetic polyfluorocarbon wax effective to form said compacted article, said wax being compatible with said 1,3-dibromo-5,5-dimethylhydantoin, or d) is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids having prior to compaction, an average particle size of at least about 175 microns, and a binder amount of a saturated, normally solid fatty amide effective to form said compacted article. 25. A method of eradicating or reducing at least Pseudomonas aeruginosa biofilm on a surface contacted by an aqueous medium or water, which method comprises introducing into the aqueous medium or water a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin effective to eradicate or at least reduce such biofilm, said amount of 1,3-dibromo-5,5-dimethylhydantoin being less than the amount of N,N'-bromochloro-5,5-dimethylhydantoin required to achieve the same degree of effectiveness, wherein the 1,3-dibromo-5,5-dimethylhydantoin used in conducting the method is the sole disinfecting agent for sanitizing the aqueous medium, and wherein the 1,3-dibromo-5,5-dimethylhydantoin used: a) is in non-compacted form and has an average particle size of at least about 175 microns; or b) is in the form of a shape-retentive pressure compacted article devoid of any binder and consists essentially of compacted 1,3-dibromo-5,5-dimethylhydantoin solids having prior to compaction an average particle size of at least about 175 microns; or c) is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids and a binder amount or a micronized synthetic polyolefin-based hydrocarbon wax and/or a micronized synthetic polyfluorocarbon wax effective to form said compacted article, said wax being compatible with said 1,3-dibromo-5,5-dimethylhydantoin, or d) is in the form of a shape-retentive pressure compacted article consisting essentially of 1,3-dibromo-5,5-dimethylhydantoin particulate solids having prior to compaction, an average particle size of at least about 175 microns, and a binder amount of a saturated, normally solid fatty amide effective to form said compacted article. 26. A method of claim 1 wherein biofilm on a surface is eradicated or at least reduced by contacting said biofilm with an aqueous medium or water into which an amount of 1,3-dibromo-5,5-dimethylhydantoin effective to eradicate or at least reduce such biofilm has been introduced, and wherein said contacting is for one or more periods long enough to eradicate or at least reduce said biofilm. 27. A method of claim 1 wherein the aqueous medium treated is: i) recreational water and wherein the treatment of the water comprises (A) passing a sidestream of the water through a bed of the 1,3-dibromo-5,5-dimethylhydantoin such that a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin is delivered to the water, or (B) dispensing 1,3-dibromo-5,5-dimethylhydantoin from a floating device such that a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin is delivered to the water; or ii) industrial cooling water, wastewater, or process water and wherein the treatment of the water comprises passing a side stream of the water through a bed of the 1,3-dibromo-5,5-dimethylhydantoin such that a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin is delivered to the water. 28. A method of claim 26 wherein said biofilm comprises at least Pseudomonas aeruginosa biofilm on said surface. 29. A method of claim 1 wherein said 1,3-dibromo-5,5-dimethylhydantoin is continuously or periodically dispensed into the aqueous medium in an amount effective to concurrently eradicate or at least reduce biofilm on surfaces contacted by such aqueous medium or water, and to effect microbiological control of microbial species present in said aqueous medium or water. 30. A method of claim 29 wherein the treatment of the aqueous medium or water comprises dispensing 1,3-dibromo-5,5-dimethylhydantoin into a sidestream of the aqueous medium or water, and flowing the resultant treated sidestream into a larger body of the aqueous medium or water. 31. A method of claim 29 wherein the treatment of the water comprises dispensing 1,3-dibromo-5,5-dimethylhydantoin from a floating device such that a biocidally effective amount of 1,3-dibromo-5,5-dimethylhydantoin is delivered to the water. 32. A method of claim 29 wherein the water being treated is recreational water, industrial cooling water, wastewater, or process water. 33. A method of claim 24 wherein said biofilm comprises extra-cellular polysaccharide. 34. A method of claim 33 wherein said biofilm harbors at least one pathogen. OR REPRODUCING AUDIO SIGNAL AT DESIRED SOUND QUALITY, REDUCED DATA VOLUME OR ADJUSTED OUTPUT LEVEL
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (127)
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Fu Lu Mou-Ying (Lake Bluff IL) Adjei Akwete L. (Wadsworth IL) Gupta Pramod K. (Gurnee IL), Aerosol drug formulations containing polyglycolyzed glycerides.
Duan Daniel C. (St. Paul MN) Stefely James S. (Woodbury MN) Schultz David W. (Pine Springs MN) Leach Chester L. (Lake Elmo MN), Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Duan Daniel C. ; Stefely James S. ; Schultz David W. ; Leach Chester L., Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing propellant 134a and fluticasone propionate.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Sekins K. Michael (San Diego CA) Shaffer Thomas H. (Lansdowne PA) Wolfson Marla R. (Wyndmoor PA), Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation.
Bonte Frdric (Boulogne FRX) Dehan Michel (Verrieres le Buisson FRX) Le Ridant Alain (Neuilly sur Seine FRX) Puisieux Francis (Maisons Alfort FRX) Taupin Christiane C. (Orsay FRX), Artificial surfactants, pharmaceutical compositions containing them and use thereof.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann,GB3 ; Taylor Anthony James,GB3 ; Wyatt David Andrew,GB3, Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canisters containing aerosol formulations containing P134a and fluticasone propionate.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Trevino Leo A. (San Diego CA) Dellamary Luis A. (San Marcos CA) Tarara Thomas E. (San Diego CA) Weers Jeffry G. (San Diego CA) Ranney Helen M. (La Jolla CA), Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents.
Illum Lisbeth (Nottingham GBX), Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving mater.
Fuhrman Bradley P. (Buffalo NY) Flaim Stephen F. (San Diego CA) Hernan Lynn J. (Buffalo NY) Nesti Frances D. (Shelburne VT) Papo Michele C. (Buffalo NY) Steinhorn David M. (Eggertsville NY), Fluorocarbons as anti-inflammatory agents.
Byron Peter R. (Richmond) Dalby Richard N. (Richmond VA), Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Byron Peter R. (Richmond VA) Dalby Richard N. (Richmond VA), Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Kaufman Robert J. ; Richard Thomas J. ; Stephens Richard A. ; Goodin Thomas H. ; Allen John S. ; Layton Tony E., Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal.
Cloosterman Aloysius B. M. (Emmerich DEX) Kranenburg Simon V. (Ijssel NLX), Lipid and protein containing material in particulate form and process therefor.
Byron Peter R. (Richmond VA) Blondino Frank E. (Richmond VA), Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable.
Johansson Eric T. ; Ritson Carl ; Rubsamen Reid M., Method and apparatus for releasing a controlled amount of aerosol medication over a selectable time interval.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissue and controlling their r.
Tice Thomas R. ; Gilley Richard M. ; Eldridge John H. ; Staas Jay K., Method for delivering bioactive agents into and through the mucosally-associated lymphoid tissues and controlling their.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Lichtenberger Lenard M. (Houston TX 4), Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy.
Johnson Keith A. (Sunnyvale CA) Gordon Marc S. (Sunnyvale CA) Lyons Shirley W. (Sunnyvale CA), Methods and system for processing dispersible fine powders.
Unger Evan C. ; Fritz Thomas A. ; Matsunaga Terry ; Ramaswami VaradaRajan ; Yellowhair David ; Wu Guanli, Methods of preparing gas and gaseous precursor-filled microspheres.
Egan Edmund A. ; Holm Bruce A. ; Ferguson William H., Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction.
Bernstein Howard (Cambridge MA) Zhang Yan (Cambridge MA) Khan M. Amin (Downingtown PA) Tracy Mark A. (Arlington MA), Modulated release from biocompatible polymers.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Sutton Andrew D. (Ruddington GB2) Johnson Richard A. (West Bridgford GB2) Senior Peter J. (Near Melbourne GB2) Heath David (The Park GB2), Preparation of diagnostic agents.
Osborne Nicholas,GBX ; Sutton Andrew Derek,GBX ; Johnson Richard Alan,GBX, Preparation of hollow microcapsules by spray-drying an aqueous solution of a wall-forming material and a water-miscible.
Platz Robert M. (Half Moon Bay CA) Winters Mark A. (Mountain View CA) Pitt Colin G. (Thousand Oaks CA), Pulmonary administration of granulocyte colony stimulating factor.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Systemic administration of a therapeutic preparation.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Systemic administration of a therapeutic preparation.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic delivery systems related applications.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic drug delivery systems.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
McManus, Samuel P.; Riley, Timothy A.; Culbertson, Sean M.; Kozlowski, Antoni; Fry, Dennis G.; Youso, Patrick D., Complexes of small-interfering nucleic acids.
Vehring, Reinhard; Hartman, Michael Steven; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems.
Vehring, Reinhard; Hartman, Michael Steven; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Jumar, Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions, methods and systems for respiratory delivery of two or more active agents.
Vehring, Reinhard; Hartman, Michael Steven; Lechuga-Ballesteros, David; Smith, Adrian Edward; Joshi, Vidya B.; Dwivedi, Sarvajna Kumar, Compositions, methods and systems for respiratory delivery of two or more active agents.
McManus, Samuel P.; Riley, Timothy A.; Culbertson, Sean M.; Kozlowski, Antoni; Fry, Dennis G.; Yuan, Xuejun; Sheng, Dawei; Dixit, Vidula R., Conjugates of small-interfering nucleic acids.
Burkhardt, Frederick J.; Debono, Manuel; Nissen, Jeffrey S.; Turner, Jr., William Wilson, Cyclic peptide antifungal agents and process for preparation thereof.
Weers, Jeffry G.; Rao, Nagaraja; Huang, Daniel; Miller, Danforth; Tarara, Thomas E., Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases.
Tarara, Thomas E.; Weers, Jeffry G.; Eldon, Michael A.; Narashimhan, Rangachari; Clark, Andrew, Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use.
Bloom, Corey Jay; Crew, Marshall David; Smithey, Daniel Tod; Miller, Warren Kenyon; Morgen, Michael Mark, Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer.
Straub, Julie; Altreuter, David; Bernstein, Howard; Chickering, III, Donald E.; Khattak, Sarwat; Randall, Greg, Porous drug matrices and methods of manufacture thereof.
Tarara, Thomas E.; Weers, Jeffrey G.; Kabalnov, Alexey; Schutt, Ernest G.; Dellamary, Luis A., Pulmonary delivery particles comprising an active agent.
Cancilla, Mark; Cunningham, James J.; Flanagan, Michael W.; Haringsma, Henry J.; Kenski, Denise; Stanton, Matthew G.; Stirdivant, Steven M.; Willingham, Aarron, RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA).
Cancilla, Mark; Cunningham, James John; Flanagan, William Michael; Haringsma, Henry J.; Kenski, Denise M.; Stanton, Matthew G.; Stirdivant, Steven M.; Willingham, Aarron T., RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA).
Dellamary, Luis A.; Reiss, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E., Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery.
Dellamary, Luis A.; Riess, Jean; Schutt, Ernest G.; Weers, Jeffry G.; Tarara, Thomas E., Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use.
Dellamary, Luis A; Riess, Jean; Schutt, Ernest G; Weers, Jeffry G; Tarara, Thomas E, Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.